- In this video, Dr. Martin Reck discusses the emergence of the immunotherapy and the positive results of four randomized trials on immunotherapy vs. chemotherapy, showing benefit in overall survival. Dr. Reck also mentions that in selected patients immunotherapy might be better than chemotherapy and the treatment plan for a specific population of patients with autoimmune diseases at the baseline.
- Therapy of EG for mutated lung cancer was discussed during the world conference on lung cancer held in Vienna. A lot of new data and already available data on EG for mutated lung cancer was discussed in detail during the conference. Dr. Federico Cappuzzo, (Director Medical Oncology Department, at Ospedale Civile, Livorno) gave a lot insights about the management of EG for mutated NSCLC with the new molecule osimertinib, the new strategy of diagnosis based on clinical practice and the new management approach of NSCLC.
- This session with Dr. Felip discusses the overall landscape of ALK inhibitors for treatment of NSCLC. She discusses the various available ALK inhibitors currently including crizotinib, ceritinib, alectinib and the possible treatment modalities with these drugs either as monotherapy or in combination. She also gives a brief overview of the various randomized trials which have had positive results with these inhibitors and stressed on the need for further trials and data in this area.